Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question
Report Includes:
- An introduction to interleukin-2 (IL-2) and identification of its applications
- Insights into the latest trends and technologies in the IL-2 research and development
- Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
- Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile
- Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
- An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)
CHAPTER 1 INTRODUCTION
Introduction
Interleukin-2 an Important Driver for T Cell Homeostasis
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 A BALANCING ACT
Targeted Effects
Off-Target Effects
CHAPTER 3 APPROVED IL-2 THERAPIES
IL-2 Antagonist Immunosuppressant
Simulet (Basilximab) Novartis
Zenapax (Daclizumab) Roche
Zinbryta (Daclizumab) AbbVie/Biogen
Leukotac (Iolimomab) ElsaLys Biotech
IL-2 Agonist Cancer Immunotherapy
Proleukin (Aldesleukin) Novartis/Chiron
CHAPTER 4 FUTURE OPPORTUNITIES
New Strategies to Harness IL-2's Potential
IL-2 Monoclonal Antibodies
IL-2 Antibody Drug Conjugates
IL-2 Antibody?Cytokine Fusion Proteins
IL-2 Mutant Superkines
IL-2 Therapeutic Protein Inhibitor
IL-2 Immunotoxins
IL-2 Radioimmunoconjugates
Long-Acting Recombinant IL-2
IL-2 Based Vaccines
CHAPTER 5 IL-2 WATCH FOR THESE DRUGS
CHAPTER 6 REFERENCES
Introduction
Interleukin-2 an Important Driver for T Cell Homeostasis
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 A BALANCING ACT
Targeted Effects
Off-Target Effects
CHAPTER 3 APPROVED IL-2 THERAPIES
IL-2 Antagonist Immunosuppressant
Simulet (Basilximab) Novartis
Zenapax (Daclizumab) Roche
Zinbryta (Daclizumab) AbbVie/Biogen
Leukotac (Iolimomab) ElsaLys Biotech
IL-2 Agonist Cancer Immunotherapy
Proleukin (Aldesleukin) Novartis/Chiron
CHAPTER 4 FUTURE OPPORTUNITIES
New Strategies to Harness IL-2's Potential
IL-2 Monoclonal Antibodies
IL-2 Antibody Drug Conjugates
IL-2 Antibody?Cytokine Fusion Proteins
IL-2 Mutant Superkines
IL-2 Therapeutic Protein Inhibitor
IL-2 Immunotoxins
IL-2 Radioimmunoconjugates
Long-Acting Recombinant IL-2
IL-2 Based Vaccines
CHAPTER 5 IL-2 WATCH FOR THESE DRUGS
CHAPTER 6 REFERENCES
LIST OF TABLES
Table 1: Expression of CD25, CD122 and CD132 in Immune and Nonimmune Cells
Table 2: Selection of Clinical Studies With IL-2 Drugs at Different Doses on Different Targets
Table 3: IL-2 Agents to Watch
Table 1: Expression of CD25, CD122 and CD132 in Immune and Nonimmune Cells
Table 2: Selection of Clinical Studies With IL-2 Drugs at Different Doses on Different Targets
Table 3: IL-2 Agents to Watch
LIST OF FIGURES
Figure 1: IL-2 Signaling Pathways and Their Primary Biological Effects in Different Immune Cell Types
Figure 2: Three Different Types of IL-2 Receptors
Figure 3: Balancing Efficacy and Safety
Figure 4: Drugs Targeting IL-2
Figure 5: Computer Model of Neoleukin-2/15 Structure
Figure 1: IL-2 Signaling Pathways and Their Primary Biological Effects in Different Immune Cell Types
Figure 2: Three Different Types of IL-2 Receptors
Figure 3: Balancing Efficacy and Safety
Figure 4: Drugs Targeting IL-2
Figure 5: Computer Model of Neoleukin-2/15 Structure
